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ABSTRACT
Introduction: Cystic fibrosis is a chronic disease with multiple organ involvement and chiefly results in chronic respiratory 
infections, pancreatic insufficiency and associated complications. The age at diagnosis, clinical presentation, rate of disease 
progression and prognosis is variable among patients. This study is designed to evaluate the behavior of disease to provide 
epidemiologic data for early recognition and proper management.
Material and methods: The study was designed as an active surveillance of 192 patients diagnosed with cystic fibrosis in 
a tertiary lung disease centre between 2008 and 2015. The diagnosis of cystic fibrosis was established in all patients accordingly 
to conventional criteria, including two positive sweat chloride tests and clinical signs and symptoms. Demographic, clinical and 
laboratory data were obtained from these patients in each hospitalization and also every follow-up visit and carefully evaluated 
for complications of this chronic disease.
Results: The majority of patients showed positive culture for Pseudomonas aeroginosa. Bronchiectasis was the most prevalent 
finding in chest CT scan. 44.3% of patients had been treated for allergic bronchopulmonary aspergillosis and all had sinus disease. 
Increased pulmonary artery pressure was observed in 40% of patients with cystic fibrosis. 33 patients died which consisted 17.1% 
of all the patients.The mean age of mortaliy was 18.15 year.
Conclusions: The clinical outcome of cystic fibrosis is variable in different countries which may reflect environmental influences 
and the role of early diagnosis on long term outcomes. However, the role of early diagnosis in long-term outcomes of the disease 
can not be ignored. 
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Introduction 
Cystic fibrosis is a disease with multiple or-
gan involvement that mainly results in chronic 
respiratory infections, pancreatic insufficiency 
and associated complications. The long-term 
outcome of multi-organ involvement has been 
studied by several researches; however, the point 
of care for these patients should be determined 
by the specific organ involved and the nature of 
pathogen microorganism.
Cystic fibrosis has an autosomal recessive 
pattern of inheritance conditioned by a mutant 
gene on the long arm of chromosome 7 which 
encodes cystic fibrosis transmembrane conduc-
tance regulator (CFTR). With any modification of 
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CFTR, the ion transfer in the epithelium is altered. 
Therefore, the thickening of epithelial secretions 
increases and also a significant reduction of the 
action of mucociliary transport and beta-defen-
sing ensues. The result is an increased pro-in-
flammatory activity which is the initiation point 
of many complications of cystic fibrosis. Age at 
diagnosis varies widely among these patients. 
Median age at diagnosis according to literature 
is 6−8 months. Respiratory symptoms may inc-
lude cough, recurrent wheezing, atypical asthma, 
dyspnea on exertion and chest pain. Physical si-
gns depend on the progression of disease such as 
tachypnea, respiratory distress with retractions, 
wheeze or crackles, increased anteroposterior 
chest diameter, clubbing, cyanosis, hyperresonant 
chest on percussion and nasal polyps. The diagno-
sis of cystic fibrosis is based typically on clinical 
manifestations, family history, and positive sweat 
chloride test results.
The course of disease and prognosis is tre-
mendously variable among patients due to va-
riability in organ involved. According to the 
literature there is a gender gap in cystic fibrosis, 
with males tending to do better than female co-
unterparts [1, 2]. The lungs are normal at birth 
and after birth, before the onset of infection and 
inflammation. Infections become established 
with a distinctive bacterial flora. Failure of opso-
nophagocytosis leads to bacterial persistence. 
The most common bacterial pathogens isolated 
from the sputum culture of patients with cystic 
fibrosis are Hemophilus influenza, Staphylococcus 
aureus, Pseudomonas aeroginosa, Burkholderia 
cepacia, E.coli and Klebsiella pneumoniae. S.au-
reus is one of the three most common organisms 
in cystic fibrosis lung infections and is associated 
with advanced pulmonary disease. Colonization 
with P.aeroginosa is an unfavorable event in the 
clinical course of the patients with cystic fibrosis.
Typically, peripheral airway involvement 
resulting from cystic fibrosis, manifests as an 
obstructive defect with air-trapping and hype-
rinflation. Progression of the disease has been 
correlated with a change in forced expiratory 
volume in one second (FEV1) [3]. It has been 
reported that exposure to second-hand smoke 
adversely affects both cross-sectional and longi-
tudinal measures of lung function in individuals 
with cystic fibrosis [4]. Allergic bronchopulmo-
nary aspergillosis affects approximately 7−9% 
of patients with cystic fibrosis. It is relatively 
uncommon in childhood. The clinical criteria 
for the diagnosis of allergic bronchopulmonary 
aspergillosis development have been recently 
proposed and a certain number of these criteria 
should be present to make the diagnosis of aller-
gic bronchopulmonary aspergillosis. A problem 
with applying the criteria in children with cystic 
fibrosis is that many of the criteria could also 
be due to the underlying disease. Cystic fibrosis 
may express itself in the classical manner or in 
an atypical way. Inflammation of the paranasal 
sinuses has been found in 74−100% of patients 
and nasal polyps in 6 to 44%.
This study is designed to provide epidemiolo-
gic data useful for better evaluation and treatment 
of cystic fibrosis.
Material and methods
The study was designed as an active surveil-
lance of 192 male and female patients diagnosed 
with cystic fibrosis in a tertiary referral lung di-
sease centre (National Research Institute of Lung 
Disease) between 2008 and 2015. 
The study was reviewed and approved 
by the Shahid Beheshti University of Medical 
Sciences Ethics Committee. All procedures per-
formed in this study were in accordance with 
the ethical standards of the institutional and/or 
national research committee and with the 2000 
Declaration of Helsinki (http://www.wma.net/e/
policy/b3.htm) and its later amendments. In-
formation about the study was given compre-
hensively both orally and in written form to all 
patients or their accompanying adult. They gave 
their informed written consents prior to their 
inclusion in the study.
The diagnosis of cystic fibrosis was esta-
blished in all patients accordingly to conven-
tional criteria, including two positive sweat 
chloride tests and clinical signs and symptoms. 
Demographic, clinical and laboratory data were 
obtained from these patients in each hospitaliza-
tion and also every follow-up visit and carefully 
evaluated for complications of this chronic dise-
ase. Follow-up visits were set every 6 months if 
patients had no incidents of any exacerbation. If 
patients were admitted to hospital due to an emer-
gency situation, their lab and radiologic data were 
reclaimed through National Health System from 
their admission file. At every visit, all necessary 
physical exam, laboratory or radiological exams 
were acquired if requested by physician.
Results
Total number of 192 patients with confirmed 
diagnosis of cystic fibrosis were enrolled in the 
Advances in Respiratory Medicine 2016, vol. 84, no. 6, pages 310–315 
312 www.journals.viamedica.pl
Table 1. Demographic variables of patients
Variable
Age at the time of diagnosis 2.5 year
Sex (male/female) 60.4%/39.6%
Age at onset of the initial presentation
   > 5 year
   1−5 year
   < 1 year
20.2%
10.6%
66.2%
Table 2. Pathogenes cultured positive in lung sputum of 
cystic fibrosis patients (%)
Sputum culture Positive 
Pseudomonas aeroginosa 72.0
Staphylococcus aureus 25.4
Candida albicans 9.6
Aspergillus fumigates 8.8
E.coli 1.5
Klebsiella pneumoniae 1.5
Burkholderia cepacia 0.5
Table 3.  High-resolution computed tomography (HRCT) 
scan findings of cystic fibrosis patients (%)
HRCT scan findings Positive Negative
Bronchiectasis 96.5 3.5
Consolidation 83.3 16.7
Collapse 81.2 18.8
Hyperinflation 98 2
study. Demographic variables are presented in 
Table 1. The median age at diagnosis was ap-
proximately 2.5 year, and 60.4% of the patients 
were male and 39.6% of them were female. From 
192 patients, 67.6% of the patients belonged to 
consanguineous families.
 Sputum culture isolates
Sputum cultures were obtained during each 
hospitalization or at every visit. All the cultures 
were evaluated generally (not specifically indi-
vidualized in each patient). From all the sputum 
specimens, 72% showed positive culture for 
Pseudomonas aeroginosa, 25.4% for Staphylo-
coccus aureus, and 9.6% for Candida albicans. 
Surprisingly only one out of 192 patients showed 
positive sputum culture for Burkholderia cepacia 
(Table 2). 18.8% of our patients with second-hand 
smoke exposure had positive sputum cultures 
for methicillin-resistant Staphylococcus aureus 
(MRSA). Computed tomography (CT) findings in 
sputum culture positive patients for Aspergillosis 
were classified and 97% of patients with hype-
rinflation and 76.9% with collapse were positive 
for Aspergillosis.
HRCT scan findings
Various chest CT findings in cystic fibrosis 
patients were recorded during follow-up time. 
These chest CT findings are depicted in Table 3. 
The most prevalent finding is bronchiectasis 
observed in 96.5% of patients.
Clinical findings
Various clinical findings during follow-up 
time are depicted in Table 4. During their ad-
mission, 44.3% of patients had been treated for 
allergic bronchopulmonary aspergillosis (ABPA) 
and 100% had sinus disease during the course of 
their disease. Increased pulmonary artery pressu-
re (PAP) was observed in 40% of patients with CF 
during 7 years follow-up time.
Mortality rate
 During follow-up, 33 out of 192 patients 
died which consisted 17.1% of all the patients. 
Gender distribution among these dead patients 
was more significant in males and included 22 
patients out of 116 (18.9%). Female mortality only 
consisted of 11 patients out of 76 patients (14%). 
Mortality was associated with raised pulmonary 
artery pressure in 33.3% of cases in our study. The 
mean age of mortality among these patients was 
18.15 year. Figure 1 demonstrates the distribution 
of mortality in different age groups in male and 
female patients.
Table 4.  Various clinical findings during follow-up time in 
cystic fibrosis patients (%)
Positive Negative
Allergic bronchopulmonary 
aspergillosis
44.3 55.7
Sinus disease 100 0
Failure to thrive (FTT) 89.5 10.5
Vitamin D deficiency 49 51
Diabetes 2.5 97.5
Increased pulmonary artery 
pressure (PAP)
40 60
High serum IgE 44.3 55.7
Maryam Hassanzad et al., Long term outcome of cystic fibrosis 
313www.journals.viamedica.pl
Discussion
The main point of this study is to show the 
various clinical findings and mortality rate of 
cystic fibrosis patients after 7 years follow-up. 
Overall, 7 years mortality was 17.1% (33 indivi-
duals) in our patients. Previously, cystic fibrosis 
was invariably assumed to be fatal during early 
childhood [5]. Today, the average life expectancy 
is 35 years and therefore cystic fibrosis is no more 
considered an exclusively pediatric disease [5]. 
With patients living longer and reaching adul-
t-hood, complications play a major role in the 
development of complaints which are still a chal-
lenge for physicians in both outpatient and acute 
settings [6].
The median age of diagnosis in our patients 
was 2.5 year. The median age of diagnosis of cystic 
fibrosis according to literature is 6 to 8 months. 
The later age of diagnosis in our patients could 
be due to later referral time. This may affect the 
long-term prognosis and outcome.
There was also a male preponderance among 
the patients evaluated. Considering mortality 
among these patients, death was significantly 
much more prevalent in our male patients, ap-
proximately twice the female patients. This was 
in contrast with previous cohorts who were indi-
cative of a worst survival and a lower overall life 
expectancy in female patients than the males [7, 8]. 
None of our patients died in the first year of 
life and even in the first decade of life and this 
is the result of improved management of cystic 
fibrosis in recent years. However, no single new 
therapeutic intervention can be identified as the 
reason for this improved survival. 
Consanguinity is known to be the main cause 
of genetic disorders and there is a greater risk of 
occurrence of cystic fibrosis in populations with 
high levels of consanguineous marriage. The 
overall rate of consanguineous marriage among 
Iranians is approximately 38.6% with a range of 
30−85% in different provinces. In this study, 
67.6% of the patients with cystic fibrosis belonged 
to consanguineous families [9]. 
Cystic fibrosis lung is affected in an extraordi-
nary complex manner and cystic fibrosis patients 
have a unique set of bacterial pathogens that are 
acquired in an age-dependent manner. According 
to literature, common pathogens cultured from 
the respiratory tract of young children with cystic 
fibrosis which cause endobronchial infections 
during childhood are S.aureus and non-typeable 
H.influenzae. In cystic fibrosis patients, the pre-
dominant site of infection with S.aureus, is the 
oropharynx rather than the anterior nares [10]. La-
ter, as the patient ages, the major organisms which 
involve the respiratory tract are P.aeroginosa and 
B.cepacia. It has been shown that a host enzyme 
with bactericidal activity, sPLA2-IIA, increase 
age-dependently in expectorations of patients 
with cystic fibrosis. These amounts are enough 
to kill S.aureus but only marginally influence the 
P.aeroginosa strains. P.aeroginosa isolates from 
Figure 1. The distribution of mortality among different age groups in male and female patients
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CF patients are capable to induce sPLA2-IIA 
expression in bronchial epithelial cells which are 
known as the major source of the enzyme. Hence, 
P.aeroginosa contributes to S.aureus eradication 
in CF airway [11]. Our results suggested that one 
species of bacterium could eradicate another one 
by manipulating the host. 
Pseudomonas was more frequently cultured 
from the sputum of the older patients in our 
study (28% in patients less than 5 yr old vs. 
44% in patients older than 5 yr old). In a stu-
dy performed in 2011−2012 nearly half of the 
cystic fibrosis patients were diagnosed by P.ae-
roginosa [12]. P.aeroginosa is considered to be 
the most significant pathogen in these patients 
also because of its association with worsening 
of the pulmonary status. In our previous study 
performed in 2009−2010, P.aeroginosa was one 
of the main risk factors of patients’ death [13]. 
Its eradication is really difficult despite inten-
sive antibiotic treatments. The co-existence of 
multiple phenotypes of P.aeroginosa with highly 
resistance to any antimicrobial treatment is one 
of its most striking characteristics in chronic lung 
involvement in cystic fibrosis. This was strongly 
consistent with our findings in these patients. As 
most of them with positive pseudomonas sputum 
cultures were infected with resistant strains to 
two or even more antimicrobial agents such as 
cefepime, ceftazidime, amikacin and gentamicin. 
Colistin was the antimicrobial agent with the least 
degree of resistance in our study, may be due to 
the fact that it has been much less available than 
the above mentioned agents. 
Aspergillus fumigatus is another pathogen 
with an important role in cystic fibrosis lung dise-
ase and is frequently isolated from cystic fibrosis 
patients. This role is not exclusively in the context 
of ABPA. In our study 8.8% of our patients had 
positive sputum cultures with Aspergillus. It has 
been shown that cystic fibrosis patients with colo-
nization of this fungus experience more frequent 
hospitalizations, with more prominent radiolo-
gical abnormalities and a lower lung capacity 
than others without colonization [14]. Chest ra-
diographs in patients with cystic fibrosis usually 
reveal degrees of hyperinflation, dilated bronchi 
with thickened walls as well as well-defined areas 
of air-space opacification or nodules due to muco-
id impaction, atelectasis, cavities and hilar lym-
phadenopathies. Pneumothorax is also frequently 
seen and can be recurrent. While the radiologic 
evaluation of our cystic fibrosis patients revealed 
hyperinflation in 98% of patients, bronchiectasis 
in 96.5% of the patients, consolidation in 83.3% of 
patients and collapse atelectasis in 81.3% of them 
which are similar to our earlier studies [15, 16], 
colonization with aspergillus associated with 
hyperinflation, bronchiectasis, consolidation and 
atelectasis were reported as 5.9%, 9.1%, 6.3% and 
13.3%, respectively. 
Candida infections are not rated as a priority 
by cystic fibrosis patients and may simply reflect 
contamination of the sputum but airway coloni-
zation with Candida albicans has been associated 
with a greater rate of FEV1 decline and hospital-
-treated exacerbations in cystic fibrosis [17, 18]. 
In our study, Candida cultures were classified 
based on FEV1 of patients which 28.6% of candida 
culture positive had FEV1 > 80% and 71.4% had 
FEV1 < 80%. This could be an issue for further 
studies.
The prevalence of rhinosinusitis in the cy-
stic fibrosis patients reaches 100% [19]. Cystic 
fibrosis patients have a high susceptibility for 
a sinus disease. This may be related to altered 
properties of their mucous secretions, leading 
to impaired mucociliary clearance. It has been 
suggested that the CFTR mutation responsible 
for cystic fibrosis might be a predisposing factor 
for sinus disease, by demonstrating an increased 
occurrence of CFTR mutations in the general po-
pulation with chronic rhinosinusitis. In our study 
100% of the patients were suffering from chronic 
sinus disease which significantly influenced their 
quality of life. 
According to literature, pulmonary artery 
pressure is raised in adults and correlates well 
with pulmonary disease severity and survival [20]. 
However, FEV1 and PaO2, have been suggested as 
stronger predictors of death in these patients [20]. 
In our study, 60% of patients had normal pul-
monary artery pressure and a raised pulmonary 
artery pressure was seen in 40% of them. Raised 
pulmonary artery pressure was associated with 
mortality in 33.3% of cases in our study. Howe-
ver, most of the mortality associated with cystic 
fibrosis results from progressive lung disease. 
Patients with respiratory disease may experience 
a steady decline in lung function, with eventual 
development of cor pulmonale, respiratory fa-
ilure and death. In a Canadian cohort modifiable 
risk factors such as malnutrition and pulmonary 
exacerbations are associated with an increased 
risk of death [21].
Although failure to thrive is a hallmark 
of the disease but surprisingly 10.5% of our 
patients did not show any growth failure. This 
may be explained by mutations with less severe 
forms of presentation of the disease. To evaluate 
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the disease severity, scoring systems such as 
“Shwachman-Kulczycki score system” are availa-
ble [22]. It also underscores this fact that higher 
socioeconomic status of the family with better 
provision of nutritional supplements may greatly 
influence the growth of the child.
Children who already have a lung disease 
such as cystic fibrosis and asthma are at greater 
risk for health problems when they are exposed 
to tobacco smoke [23]. Research has shown these 
children have a greater decline in lung function 
and their disease worsens or progresses more than 
those who are not exposed. Lung damage from 
second-hand smoke exposure can happen silently 
even if the child does not seem to have any symp-
toms. Children with cystic fibrosis exposed to 
second-hand smoke not only are confronted with 
diminished growth and increased air-trapping, 
but also have MRSA isolated from their respira-
tory cultures more frequently [24]. We evaluated 
our patients with second-hand smoke exposure 
for MRSA and we found that 18.8% of these pa-
tients had positive sputum cultures for MRSA.
Conclusion
The clinical outcome of cystic fibrosis is 
variable in different countries. This may reflect 
environmental influences on expression of one 
single genetic disorder. However, the role of early 
diagnosis in long-term outcomes of the disease 
cannot be ignored. The final goal in patients with 
cystic fibrosis is to take steps toward better clini-
cal outcomes and to achieve a near normal life. 
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